Published April 28, 2026
| Version v1
Preprint
Open
CDKN2A-Targeted Therapy for High-Grade EMPD
Description
Open Targets identifies CDKN2A with score 0.29 for EMPD. CDKN2A encodes p16INK4a, a CDK4/6 inhibitor. Loss of CDKN2A function in EMPD could be targeted with CDK4/6 inhibitors like palbociclib, which have shown efficacy in other CDKN2A-deficient cancers.
Notes
IPFS: QmWdZXzisETD76qxTZsqy2EqXaj8jh35DMiC4TAxgaegJQ. TX: 0x5fc59599a7a2385252f8abdb8e0e1531d8ee2097bec04715cf5ee931c70d64e0. CC0.
Files
hypothesis.json
Files
(340 Bytes)
| Name | Size | Download all |
|---|---|---|
|
md5:9fdf6be68a5fc56a703d37b7ae4f59f2
|
340 Bytes | Preview Download |